Hoth Therapeutics Inc
NASDAQ:HOTH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
VF Corp
NYSE:VFC
|
US |
HOTH's latest stock split occurred on Oct 26, 2022
The company executed a 1-for-25 stock split, meaning that for every 25 shares held, investors received 1 new share.
Before the split, HOTH traded at 0.24 per share. Afterward, the share price was about 5.92.
The adjusted shares began trading on Oct 26, 2022. This was the only stock split in HOTH's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 17, 2026
|
M
|
Miwon Chemicals Co Ltd
KRX:134380
|
10-for-1
x10
|
147900 14790 KRW | 13550 13550 KRW |
|
Apr 17, 2026
|
S
|
Shenzhen Best of Best Holdings Co Ltd
SZSE:001298
|
1-for-1
x1
|
30.47 20.9438 CNY | 21.98 21.98 CNY |
|
Apr 17, 2026
|
T
|
Thanh Thanh Cong - Bien Hoa JSC
VN:SBT
|
53-for-50
x1.06
|
21899.9941 20660.3718 VND | 20650 20650 VND |
|
Apr 17, 2026
|
P
|
Pt Harta Djaya Karya Tbk
IDX:MEJA
|
7-for-6
x1.1666666666667
|
118.0001 101.1429 IDR | 111 111 IDR |
|
Apr 17, 2026
|
|
Yesco Holdings Co Ltd
KRX:015360
|
5-for-1
x5
|
80000 16000 KRW | 16110 16110 KRW |
015360
Hoth Therapeutics Inc
Glance View
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2019-02-15. The firm is also focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer; a treatment for mast-cell derived cancers and anaphylaxis, and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases. The Company’s preclinical assets for atopic dermatitis; treatment for asthma and allergies using inhalational administration; a treatment for lung diseases resulting from bacterial infections, and treatment for inflammatory bowel diseases. The firm is also developing a diagnostic device via a mobile device. Its primary development products include HT-001, HT-KIT and HT-ALZ. Its preclinical development products include HT-003, HT-004, HT-006 and HT-002. The company is also developing a COVID-19 treatment as well as a diagnostic device for the detection of viruses via a mobile device.
